Clinical trials: Tumor Pancreas
Bladder Carcinoma, Prostate Tumor
Validation Study on the Removal of EpCAM-positive Tumour Cells From Blood Collected During Tumour Surgery Using Catumaxomab/Catuvab Device
The REMOVE study was an open-label, multicenter validation study on the removal of EpCAM-positive tumor cells from blood collected during tumor surgery using the CATUVAB Kit.
- Conditions
- Bladder Carcinoma, Prostate Tumor, Gallbladder Carcinoma, Endometrial Carcinoma
- Trial name
- REMOVE (NCT06789224)
- Testing
- CATUVAB
- Where
- 6 sites in Germany
- Volunteers
- 136 people
- Sponsor
- Lindis Bloodcare GmbH
Oncology
Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols
This is an open-label, multi-center, multi-national, non-randomized rollover study designed to allow continued access to napabucasin for patients who have participated in a Boston Biomedical-sponsored study and are being treated…
- Trial name
- NCT04299880
- Testing
- Napabucasin, Nab-paclitaxel, Gemcitabine
- Where
- 7 sites in United States, France and 2 more
- Volunteers
- 7 people
- Sponsor
- Sumitomo Pharma America, Inc.
Pancreatic Cancer
Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Subjects
The purpose of this study is to evaluate increasing dose levels of VS-4718 administered in combination with gemcitabine and nab-paclitaxel in subjects with advanced cancer and to determine a recommended Phase 2 dose (RP2D) for…
- Trial name
- NCT02651727
- Testing
- Part B, Cohort 1- VS-4718, nab-paclitaxel, gemcitabine, Part B, Cohort 2- VS4718, nab-paclitaxel, gemcitabine, Part A- VS-4718, nab-paclitaxel, gemcitabine
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Verastem, Inc.
Metastatic/Locally Advanced Non-Small-Cell Lung Cancer, Metastatic/Locally Pancreatic Ductal Adenocarcinoma
Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance
UNLOCK ASP3082 is an open label, single arm, multicenter, phase 2 platform study that aims to evaluate the mechanisms of action and resistance to ASP3082 in metastatic/locally advanced Non-Samll-Cell Lung Cancer (NSCLC) and…
- Trial name
- UNLOCK ASP3082 (NCT07483983)
- Testing
- ASP3082
- Where
- 7 sites in France
- Volunteers
- 60 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
A Prospective Registry for Patients at High-Risk for Pancreatic Cancer
This study aims to facilitate discovery and validation of tests for early detection in subjects at high risk for pancreatic ductal adenocarcinoma (PDAC) and to facilitate the use of state-of-the-art machine learning-based…
- Conditions
- Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06151223
- Testing
- Bio-specimen Collection: Blood, Bio-specimen Collection: Pancreatic Juice, MRI
- Where
- United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Pancreatic Cancer
Early Palliative Care for Patients With Advanced Pancreatic Cancer.
Pancreatic adenocarcinoma is one of the deadliest cancers. Patients with pancreatic cancer experience marked physical suffering, psychological distress and resource-demanding care at the end-of-life.
- Trial name
- EarlyCarePan (NCT04632303)
- Testing
- Early Palliative Care
- Where
- Denmark
- Volunteers
- 250 people
- Sponsor
- Inna Chen, MD
Pancreatic Adenocarcinoma
Gemcitabine, Nab-Paclitaxel, Cisplatin and Anakinra Treatment on Patients With Pancreatic Cancer
The objective of this study is to improve survival by the addition of anakinra to the chemotherapy combination of nab-paclitaxel, gemcitabine, and cisplatin in patients with resectable or potentially resectable pancreatic…
- Trial name
- NCT02550327
- Testing
- Nab-paclitaxel, Gemcitabine, Cisplatin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Baylor Research Institute
Pancreatic Cancer Non-resectable
Tunlametinib + AG + Cetuximab β as First-Line Therapy for Advanced Pancreatic Cancer
This study is a prospective, open-label, single-arm clinical trial evaluating the safety and efficacy of tunlametinib in combination with gemcitabine/albumin-bound paclitaxel and an EGFR monoclonal antibody as first-line therapy…
- Trial name
- NCT07302841
- Testing
- Experimental: Tunlametinib+gemcitabine+albumin paclitaxel + cetuximab β
- Volunteers
- 28 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Pancreatic Cancer
Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer
A phase II study combining pembrolizumab with olaparib in metastatic pancreatic adenocarcinoma patients with high tumour mutation burden
- Trial name
- NCT05093231
- Testing
- Pembrolizumab, Olaparib
- Where
- 17 sites in Australia, United Kingdom
- Volunteers
- 20 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Pancreatic Adenocarcinoma
QL1706 Plus Chemotherapy With AG Regime as First-line Treatment of Advanced PDAC
This is a single-center, open-label, exploratory study to evaluate the efficacy and safety of QL1706 plus nab-paclitaxel and gemcitabine as first-line treatment in patients with unresectable locally advanced or metastatic…
- Trial name
- NCT06750861
- Testing
- QL1706
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Pancreatic Neoplasms
Apatinib as Second-line Treatment of Advanced Pancreatic Cancer
The main research purpose Evaluation of objective response Apatinib second-line treatment of advanced pancreatic cancer (ORR) and the rate of progression free survival (PFS).
- Trial name
- Apslpanc (NCT02726854)
- Testing
- Apatinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Malignant Head and Neck Neoplasm, Malignant Neoplasm
Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"
The main goal of this phase of the study is to determine if objectively assessed Physical Activity (PA) levels in advanced-cancer patients are associated with health care provider (HCP)-assessed ECOG performance status and…
- Conditions
- Malignant Head and Neck Neoplasm, Malignant Neoplasm, Metastatic Malignant Neoplasm in the Neck, Metastatic Malignant Neoplasm in the Uterine Cervix
- Trial name
- NCT01365169
- Testing
- Exercise Intervention, Health Telemonitoring, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 590 people
- Sponsor
- M.D. Anderson Cancer Center
Pancreatic Cancer, Pancreatic Adenocarcinoma
EUS BD vs ERCP TP for Pancreatic Cancer
This Endoscopic Ultrasound guided Biliary Drainage (EUS-BD) vs. Endoscopic Retrograde Cholangiopancreatography (ERCP-TP) trial (BILPAL) is a randomized controlled multicenter trial that will provide evidence whether or not…
- Conditions
- Pancreatic Cancer, Pancreatic Adenocarcinoma, Biliary Tract Neoplasms, Biliary Duct Obstruction
- Trial name
- BILPAL (NCT03063554)
- Testing
- Endoscopic Ultrasound Guided Biliary Drainage, ERCP
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Weill Medical College of Cornell University
KRAS P.G12C, Pancreatic Cancer
A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.
Patients with other advanced solid tumors (excluding NSCLC and CRC) who have progressed after prior systemic therapy or are intolerant and lack satisfactory alternative treatment options, aiming to evaluate the efficacy and…
- Conditions
- KRAS P.G12C, Pancreatic Cancer, Solid Tumor
- Trial name
- NCT06008288
- Testing
- JAB-21822
- Where
- 31 sites in China
- Volunteers
- 88 people
- Sponsor
- Allist Pharmaceuticals, Inc.
Pancreatic Adenocarcinoma
Ultrasound-assisted Treatment of Inoperable Pancreatic Cancer
The investigators primary aim is to increase chemotherapeutic drug uptake in inoperable tumours The specific sub-objectives of the studies are: To quantify tumour sizes and relate it to the patient survival over time, dependent…
- Trial name
- NCT01674556
- Testing
- Gemzar
- Where
- Norway
- Volunteers
- 25 people
- Sponsor
- Haukeland University Hospital
Lung Adenocarcinoma, Breast Adenocarcinoma
Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas
The p63 gene is a recently discovered member of the p53 family located at chromosome 3q27Many studies have reported that overexpression of p63 can mimic p53 activities by binding DNA, activating transcription, and inducing…
- Conditions
- Lung Adenocarcinoma, Breast Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT01942629
- Testing
- their will be no intervention in any of the groups, the study is retrospective
- Volunteers
- 300 people
- Sponsor
- Rambam Health Care Campus
Metastatic Pancreatic Cancer
Proglumide With Gemcitabine and Nab-Paclitaxel in PatientsWith Metastatic Pancreatic Ductal Adenocarcinoma
This is a Phase I open labelled study to treat patients with metastatic pancreatic cancer with combination therapy using standard of care first line therapy with gemcitabine and nab-paclitaxel given days 1, 8, and 15 every 28…
- Trial name
- ProglumidePanc (NCT06017323)
- Testing
- Gemcitabine, Nab paclitaxel, Proglumide Dose level 1
- Where
- United States
- Sponsor
- Georgetown University
Postoperative Pain, Postoperative Complications
PERiX: Comparison of Efficacy Between Placement of Epidural Catheters X-ray Guided and LOS Technique
The use of epidural catheters for postoperative analgesia in pancreatic surgery is recommended by the guidelines of the ERAS society.
- Conditions
- Postoperative Pain, Postoperative Complications, Pancreatic Cancer, Haemodynamic Instability
- Trial name
- PERiX (NCT03685370)
- Testing
- LOS, X-ray placement
- Where
- Italy
- Volunteers
- 154 people
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
Expanded Access in Pancreatic Cancer
Expanded Access RBS2418 Treatment
This is an expanded access treatment protocol designed to provide access of RBS2418 to a single patient with pancreatic cancer.
- Trial name
- NCT05683470
- Testing
- RBS2418
- Sponsor
- Riboscience, LLC.
Healthy Subject, Pancreatic Carcinoma
Integrin Alpha-v-Beta and [18F]-R01-MG-F2 PET/CT in Measuring Response in Patients With Pancreatic Cancer and Healthy Volunteers
This pilot clinical trial studies the use of integrin alpha-v-beta [18F]-R01-MG-F2 Positron Emission Tomography/Computed Tomography (PET/CT) and Positron Emission Tomography-Magnetic Resonance Imaging in (PET/MRI) in measuring…
- Trial name
- NCT02683824
- Testing
- Computed Tomography, Laboratory Biomarker Analysis, PET/MRI scan
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Stanford University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.